Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + doxorubicin + paclitaxel + sunitinib
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This appears to be a non-standard combination of three chemotherapy agents (cyclophosphamide, doxorubicin, paclitaxel) and one targeted therapy (sunitinib). While cyclophosphamide, doxorubicin, and paclitaxel are commonly used together as AC-T regimen for breast cancer, sunitinib is typically used separately for different indications such as kidney cancer, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors. There is no established clinical use for this specific four-drug combination in the provided information.
02
Targets
DNAFLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)TOP2A (DNA topoisomerase II)VEGFR2 (Vascular endothelial growth factor receptor 2)TUBB (Tubulin (alpha and beta subunits))RTK (Receptor tyrosine kinase)
Beyond the preview
Go deeper on cyclophosphamide + doxorubicin + paclitaxel + sunitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + doxorubicin + paclitaxel + sunitinib.